Commercial Price Variation in Precision Oncology Testing Across U.S. Hospitals
Clicks: 2
ID: 324297
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Emerging Content
0.3
/100
2 views
1 readers
AI Quality Assessment
Not analyzed
Readership in this journal
EmergingRanked #57 of 93 articles by views in Health Affairs Scholar
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Abstract Introduction Precision oncology biomarker testing informs prognosis and guides treatment selection. These tests represent a growing component of cancer care costs. Methods We conducted a cross-sectional study of U.S. commercial payer-negotiated rates for biomarker tests for breast, colon, and non-small cell lung cancer, using Turquoise Health hospital pricing database. Outcomes included geographically adjusted payer-negotiated rates, within- and between-hospital price variation, and differences by payer, rurality, and hospital size, assessed using generalized linear models adjusted for multiple comparisons. Results We identified 422,515 negotiated rates for 28 biomarker tests across 2,142 hospitals. Median proportion of hospitals reporting payer-negotiated rates was 18.3% (interquartile range [IQR]:17.2%-18.8%) for panel-based and 30.3% (IQR:22.2%-37.8%) for non-panel-based tests; median negotiated rates per test were $3,704 (IQR: $3,096-$4,129) and $301 (IQR: $157-$485), respectively. Negotiated rates varied within hospitals (median within-hospital ratios: panel-based tests, 1.5 [IQR:1.4-1.5]; non-panel-based tests, 1.6 [IQR: 1.5-1.7]) and between hospitals (median between-hospital ratios: panel-based tests, 5.5 [IQR: 5.5-5.6]; non-panel-based tests, 5.2 [IQR: 5.1-5.4]). Negotiated rates varied significantly by payer for all tests. Conclusion Our findings revealed wide variation in commercial payer-negotiated rates for oncology biomarker tests, underscoring the need for pricing transparency and efforts to reduce price variation to support equitable, affordable cancer care.
| Reference Key |
openalex_W7196940140
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Maryam Mooghali, Joshua J. Skydel, Cary P Gross, Stacie B. Dusetzina, Zenta Walther, Maryam Lustberg, Joseph S. Ross, Joshua D. Wallach |
| Journal | Health Affairs Scholar |
| Year | 2026 |
| DOI |
10.1093/haschl/qxag203
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.